The P236L Delavirdine-Resistant Human Immunodeficiency Virus Type 1 Mutant Is Replication Defective and Demonstrates Alterations in both RNA 5′-End- and DNA 3′-End-Directed RNase H Activities

Documenti analoghi

• Mutants of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Resistant to Nonnucleoside Reverse Transcriptase Inhibitors Demonstrate Altered Rates of RNase H Cleavage That Correlate with HIV-1 Replication Fitness in Cell Culture
  di: Archer, Richard H., et al.
  Pubblicazione: (2000)
• Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)
  di: Demeter, L. M., et al.
  Pubblicazione: (2000)
• ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy
  di: Para, Michael F., et al.
  Pubblicazione: (1999)
• Unique progressive cleavage mechanism of HIV reverse transcriptase RNase H
  di: Wisniewski, Michele, et al.
  Pubblicazione: (2000)
• Structural Basis for the Inhibition of RNase H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed Inhibitors
  di: Su, Hua-Poo, et al.
  Pubblicazione: (2010)